Cure My Disease

Don't miss your cure!

 Log in / Sign up

A phase 2, Parallel-Group, Double-Blind study to investigate weight management with LY4086940 compared with placebo in adult participants with obesity or overweight and without type 2 diabetes

NCT ID NCT07890376

NEW Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 22, 2026 · Last updated Oct 22, 2026

Summary

The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition. Participation in the study will last about 58 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 460 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meet inclusion criteria under Master Protocol CWMM (NCT06143956) Exclusion Criteria: In addition to exclusion criteria under Master Protocol CWMM (NCT06143956) * Have any prior diagnosis of type 2 diabetes, type 1 diabetes, or rare forms of diabetes mellitus, except gestational diabetes * Have a laboratory value suggestive of diabetes * Have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have a known personal or family history (first-degree relative) of multiple endocrine neoplasia type 2A or 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma. * Within 6 months prior to screening, have taken medications (prescribed or over the counter) or alternative remedies (including herbal or nutritional supplements) that promote weight loss

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder overnutrition Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    46 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, Michigan, 48098, United States

  • CARDIAMET Investigaciones Médicas

    Buenos Aires, C1014ACP, Argentina

  • CTI Clinical Research Center

    Cincinnati, Ohio, 45212, United States

  • Central Washington Health Services Association d/b/a Confluence Health

    Wenatchee, Washington, 98801, United States

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    Buenos Aires, C1425AGC, Argentina

  • Centro Médico Viamonte

    Buenos Aires, C1120AAC, Argentina

  • Centro de Investigaciones Metabólicas (CINME)

    Buenos Aires, C1056ABI, Argentina

  • Charter Research - Lady Lake

    The Villages, Florida, 32162, United States

  • Charter Research - Winter Park

    Orlando, Florida, 32803, United States

  • Cicemo Srl

    Buenos Aires, 1424, Argentina

  • Clinvest Headlands Llc

    Springfield, Missouri, 65807, United States

  • Cotton O'Neil Diabetes & Endocrinology

    Topeka, Kansas, 66606, United States

  • Dent Neurologic Institute

    Amherst, New York, 14226, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • Endeavor Clinical Trials

    San Antonio, Texas, 78240, United States

  • FutureSearch Trials of Dallas

    Dallas, Texas, 75251, United States

  • Great Lakes Clinical Trials - Ravenswood

    Chicago, Illinois, 60640, United States

  • Headlands Research - Detroit

    Southfield, Michigan, 48034, United States

  • Headlands Research - Scottsdale

    Scottsdale, Arizona, 85260, United States

  • IMA Clinical Research Austin

    Austin, Texas, 78745, United States

  • Indago Research & Health Center, Inc

    Miami Lakes, Florida, 33016, United States

  • Instituto Médico Catamarca IMEC

    Rosario, 2000, Argentina

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, Iowa, 50266, United States

  • Knownwell

    Needham, Massachusetts, 02492, United States

  • Las Vegas Medical Research

    Las Vegas, Nevada, 89128, United States

  • Lucas Research, Inc

    Morehead City, North Carolina, 28557, United States

  • Lucas Research, Inc.

    New Bern, North Carolina, 28562, United States

  • Lucida Clinical Trials

    New Bedford, Massachusetts, 02740, United States

  • Mautalen Salud e Investigación

    Buenos Aires, C1128AAF, Argentina

  • Medical Research Partners

    Ammon, Idaho, 83406, United States

  • Monroe Biomedical Research

    Monroe, North Carolina, 28112, United States

  • New Horizon Research Center

    Miami, Florida, 33165, United States

  • NorCal Medical Research, Inc

    Greenbrae, California, 94904, United States

  • Peninsula Research Associates

    Rolling Hills Estates, California, 90274, United States

  • Quality Medical Research

    Nashville, Tennessee, 37211, United States

  • Rochester Clinical Research, LLC

    Rochester, New York, 14609, United States

  • Sovah Clinical Research-River District

    Danville, Virginia, 24541, United States

  • Stamford Therapeutics Consortium

    Stamford, Connecticut, 06905, United States

  • StudyMetrix Research

    City of Saint Peters, Missouri, 63303, United States

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida, 34652, United States

  • Texas Valley Clinical Research

    Weslaco, Texas, 78596, United States

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa

    Chandler, Arizona, 85225, United States

  • The Institute for Liver Health II dba Arizona Liver Health-Tucson

    Tucson, Arizona, 85712, United States

  • Tribe Clinical Research, LLC

    Greenville, South Carolina, 29607, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Velocity Clinical Research, Huntington Park

    Huntington Park, California, 90255, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.